Development asset linked to Vanda Pharmaceuticals Netherlands in public FDA and regional records.
pharma · Generalized Pustular Psoriasis · Schizophrenia · VNDA
Vanda Pharmaceuticals Netherlands
Vanda Pharmaceuticals Netherlands B.V.
Vanda Pharmaceuticals Netherlands drug portfolio — 19 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037, US HQ
2003 Founded
600 Employees
Public company Type
VNDA · NYSE Ticker
Company details
- Status
- Public
- HQ
- 2200 Pennsylvania Avenue NW, Suite 300E, Washington, DC 20037, US
- Founded
- 2003
- Employees
- 600
- Programs
- 60
- Drugs
- 19
- Patents
- 96
Vanda Pharmaceuticals Netherlands pipeline
Portfolio lens on 19 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Vanda Pharmaceuticals Netherlands drug portfolio — 19 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Vanda Pharmaceuticals Netherlands in public FDA and regional records.
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
US regulatory status: approved. Molecular target: Bacterial DNA gyrase.
- Target
- Bacterial DNA gyrase
- Mechanism
- Bacterial DNA gyrase inhibitor
-
Development asset linked to Vanda Pharmaceuticals Netherlands in public FDA and regional records.
-
Development asset linked to Vanda Pharmaceuticals Netherlands in public FDA and regional records.
-
iloperidone
Nervous system (N05)US regulatory status: approved. Molecular target: D(2) dopamine receptor.
- Target
- D(2) dopamine receptor
- Mechanism
- Dopamine D2 receptor antagonist
-
Development asset linked to Vanda Pharmaceuticals Netherlands in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Acetylcholinesterase.
- Target
- Acetylcholinesterase
- Mechanism
- Acetylcholinesterase inhibitor
-
US regulatory status: approved.
-
Development asset linked to Vanda Pharmaceuticals Netherlands in public FDA and regional records.
-
ponesimod
Antineoplastic and immunomodulating agents (L04)US regulatory status: approved. Molecular target: Sphingosine 1-phosphate receptor 1.
- Target
- Sphingosine 1-phosphate receptor 1
- Mechanism
- Sphingosine 1-phosphate receptor Edg-1 agonist
-
Development asset linked to Vanda Pharmaceuticals Netherlands in public FDA and regional records.
-
Development asset linked to Vanda Pharmaceuticals Netherlands in public FDA and regional records.
-
Development asset linked to Vanda Pharmaceuticals Netherlands in public FDA and regional records.
-
Development asset linked to Vanda Pharmaceuticals Netherlands in public FDA and regional records.
-
tasimelteon
Nervous system (N05)US regulatory status: approved. Molecular target: Melatonin receptor.
- Target
- Melatonin receptor
- Mechanism
- Melatonin receptor agonist
-
US regulatory status: approved. Molecular target: Substance-P receptor.
- Target
- Substance-P receptor
- Mechanism
- Neurokinin 1 receptor antagonist
-
Development asset linked to Vanda Pharmaceuticals Netherlands in public FDA and regional records.